EDX Medical Group (LON:EDX) has reached what Oberon Capital describes as a major strategic and commercial milestone with the launch of its TC100 testicular cancer testing service, according to the latest research note from Oberon Capital.
The healthcare diagnostics company is focused on developing innovative tests for cancer, cardiology and infectious diseases, with an emphasis on genetic risk assessment, early disease detection and improved clinical decision making. The report highlights that the launch of TC100 represents a significant step forward in validating EDX Medical’s long term strategy of building a portfolio of differentiated diagnostic “Super Tests” for European and global markets.
Research analyst Emma Ulker wrote: “EDX Medical is delivering on its strategy of building a portfolio of unique and clinically validated assays for genetic risk, early disease detection and characterisation focused on the areas of greatest global health and economic impact.”
The note explains that TC100 has demonstrated a very high degree of accuracy during validation studies. Importantly, the service is capable of detecting very early signs of disease and identifying the first indications of recurrence using a simple blood sample. The technology combines EDX proprietary biomarkers with established biomarkers, creating what Oberon believes is a differentiated and clinically valuable testing platform.
Emma Ulker added: “The unique nature of TC100 and its high accuracy provides broad based clinical benefit and commercial scope.”
The report also points to strong commercial potential, particularly given the high survival rates associated with early detection and treatment of testicular cancer. EDX Medical is initially targeting private healthcare markets in the UK and Nordic regions before broader European expansion.
Oberon Capital believes multiple product launches over the coming years could support substantial revenue growth. Forecasts for FY2026, FY2027 and FY2028 revenues have been revised to £1m, £20.2m and £34m respectively, following the resolution of previous supply delays affecting distributed products.
The broker also updated its EBITDA expectations, forecasting losses of £4.5m in FY2026 before moving into profitability with projected EBITDA of £3m in FY2027 and £5.9m in FY2028.
Financial and Operational Highlights
- TC100 testicular cancer testing service commercially launched
- Validation studies demonstrated high accuracy and early disease detection capability
- FY2026 revenue forecast of £1m
- FY2027 revenue forecast of £20.2m
- FY2028 revenue forecast of £34m
- FY2027 EBITDA forecast of £3m
- FY2028 EBITDA forecast of £5.9m
- Combined addressable market for the current portfolio estimated at more than £480m in the UK alone
- Expansion strategy focused initially on UK and Nordic private healthcare markets
The report further notes that EDX Medical’s commercial model is designed to be scalable and sustainable, with future opportunities potentially extending into larger public healthcare systems. Oberon estimates the combined annual addressable market value for the group’s current portfolio exceeds £480m in the UK alone, underlining the scale of the opportunity if adoption continues to build.
EDX Medical is listed on the AQSE market with a market capitalisation of approximately £40.9m at the time of the report. Key shareholders include Professor Sir Christopher Evans, who holds 36.52% of the company, alongside other strategic investors and management.
On a Final Note, Oberon Capital’s latest research note presents EDX Medical as a company progressing from development into commercial execution. The launch of TC100 appears to provide an important proof point for the group’s diagnostic platform strategy, while the prospect of additional product launches and expansion into new markets could support further growth in the years ahead.
